Pre-order Enquiry
Request Free Sample
Global Bispecific Antibody Market Insights: Impact of COVID-19 and Future Expectations to 2025
SKU ID : Maia-17512679 | Publishing Date : 01-Mar-2021 | No. of pages : 97
Request Sample
Request Customization
Check Discounts
The Bispecific Antibody market revenue was 468 Million USD in 2019, and will reach 661 Million USD in 2025, with a CAGR of 5.91% during 2020-2025.
This report elaborates the market size, market characteristics, and market growth of the Bispecific Antibody industry, and breaks down according to the type, application, and consumption area of Bispecific Antibody. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Bispecific Antibody in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Bispecific Antibody market covered in Chapter 11:
AstraZeneca (MedImmune)
Regeneron Pharmaceuticals
Ablynx
Neovii Biotech
OncoMed Pharmaceuticals
EMD Serono
MacroGenics
Jounce Therapeutics
Emergent BioSolutions
Genentech
Merus
Affimed Therapeutics
Adimab
Sanofi
Immunomedics
Roche
Pieris
Amgen
NovImmune SA
Eli Lilly
Chugai Pharmaceutical
Genmab
In Chapter 3, on the basis of types, the Bispecific Antibody market from 2015 to 2025 is primarily split into:
Catumaxomab (Removab)
Blinatumomab
Duligotumab
SAR 156597
In Chapter 4, on the basis of applications, the Bispecific Antibody market from 2015 to 2025 covers:
BsMAb for Diagnosis of Infectious Diseases
Diagnosis of Bacterial Infections
Diagnosis of Viral Infections
BsMAb for Cancer Diagnostic
BsAbs Blocking Signaling Pathways
BsAbs Targeting Tumor Angiogenesis
Specific Delivery of Effector Compounds to Targets
Bispecific Antibodies & Gene Therapy
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
2019
This report elaborates the market size, market characteristics, and market growth of the Bispecific Antibody industry, and breaks down according to the type, application, and consumption area of Bispecific Antibody. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Bispecific Antibody in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Bispecific Antibody market covered in Chapter 11:
AstraZeneca (MedImmune)
Regeneron Pharmaceuticals
Ablynx
Neovii Biotech
OncoMed Pharmaceuticals
EMD Serono
MacroGenics
Jounce Therapeutics
Emergent BioSolutions
Genentech
Merus
Affimed Therapeutics
Adimab
Sanofi
Immunomedics
Roche
Pieris
Amgen
NovImmune SA
Eli Lilly
Chugai Pharmaceutical
Genmab
In Chapter 3, on the basis of types, the Bispecific Antibody market from 2015 to 2025 is primarily split into:
Catumaxomab (Removab)
Blinatumomab
Duligotumab
SAR 156597
In Chapter 4, on the basis of applications, the Bispecific Antibody market from 2015 to 2025 covers:
BsMAb for Diagnosis of Infectious Diseases
Diagnosis of Bacterial Infections
Diagnosis of Viral Infections
BsMAb for Cancer Diagnostic
BsAbs Blocking Signaling Pathways
BsAbs Targeting Tumor Angiogenesis
Specific Delivery of Effector Compounds to Targets
Bispecific Antibodies & Gene Therapy
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years:
2015-2019Base Year:
2019Estimated Year:
2020Forecast Period:
2020-2025Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
